These key technologies include, for example, single-cell multi-omics technologies and spatial biology, patient-specific organoids, 3D bioprinting, as well as the modelling of mechanisms and disease progression using artificial intelligence. The initiative also aims to create a platform for cross-institutional collaboration to accelerate the translation of research findings into clinical practice in partnership with companies and investors. This will simultaneously generate social and economic value for Berlin.

Participants in the EC-EDI include Charité – Universitätsmedizin Berlin, the Berlin Institute of Health at Charité (BIH), the Max Delbrück Center, the Technical University of Berlin, Freie Universität Berlin, Humboldt University of Berlin, and other non-university institutions such as the Museum of Natural History and Max Planck Institutes.

The Einstein Center for Early Disease Interception is being funded with a total of 6 million euros since January 2026.

Source and further information:
https://www.mdc-berlin.de/news/press/launch-einstein-center-early-disease-interception
https://www.charite.de/forschung/themen_forschung/krankheiten_stoppen_bevor_sie_entstehen